Concepedia

Author

Takenori Akaike

Kumamoto UniversityORCID

Also Known As

T Akaike, T. Akaike, Takenori Akaike

24

Publications

819

Citations

8

H-Index

21

Concepts

All Affiliations

Kumamoto UniversityTokyo University of Pharmacy and Life SciencesSeisen UniversityTokyo Institute of Technology
TA

About

Takenori Akaike is an author at Kumamoto University specializing in medicine, oxidative stress, and pathology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

747

2

Immunology

2

2

566

3

Allergy

1

1

495

4

Biochemistry

1

1

495

5

Cell Biology

1

1

41

Takenori Akaike

×

7

Publications

796

Citations

7

H-Index

YearCitations

Pathogenesis of influenza virus-induced pneumonia: involvement of both nitric oxide and oxygen radicals.

Takenori Akaike, Yoichiro Noguchi, Sumiko Ijiri,

Proceedings of the National Academy of Sciences

1996

495

Therapeutic Effects of Imidazolineoxyl N-Oxide Against Endotoxin Shock through Its Direct Nitric Oxide-Scavenging Activity

Masami Yoshida, Takenori Akaike, Yuki Wada,

Biochemical and Biophysical Research Communications

1994

140

Cytotoxicity and Apoptotic Inducibility of Vitex agnus-castus Fruit Extract in Cultured Human Normal and Cancer Cells and Effect on Growth.

Kunio Ohyama, Takenori Akaike, Chieko Hirobe,

Biological and Pharmaceutical Bulletin

2003

71

Human gastric signet ring carcinoma (KATO-III) cell apoptosis induced by Vitex agnus-castus fruit extract through intracellular oxidative stress

Kunio Ohyama, Takenori Akaike, Masahiko Imai,

The International Journal of Biochemistry & Cell Biology

2005

41

TNF-alpha bifunctionally induces proliferation in primary hepatocytes: role of cell anchorage and spreading

Yoshifumi Watanabe, Hikaru Osaki, Takenori Akaike

The Journal of Immunology

1997

23

Primary cultured murine hepatocytes but not hepatoma cells regulate the cell number through density-dependent cell death.

Kenta Shinzawa, Y Watanabe, Takenori Akaike

PubMed

1995

14

Updated results from first-in-human phase 1 dose-escalation trial of TAK-102, a GPC3-targeted armored CAR T cells, in patients with advanced solid tumors.

Takako Eguchi Nakajima, Yasutoshi Kuboki, Masaru Fukahori,

Journal of Clinical Oncology

2024

12

Page 1